Neoplasms

All Conditions

Digestive System Diseases

Rare Diseases

Carcinoma

Stomach Neoplasms

Carcinoma, Signet Ring Cell

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adenocarcinoma

Neoplasms, Cystic, Mucinous, and Serous

Stomach Cancer

Diffuse Gastric Cancer

There were no special interventions for the two groups.

Without any intervention

Gastric signet ring cell carcinoma (GSRCC) possesses unique epidemiology and pathogenesis in the field of cancer, but its incidence is low. Unfortunately, there is currently a lack of systematic research focusing on the prognostic proteomic features of GSRCC. Given this knowledge gap, this study aims to comprehensively characterize the proteomic landscape of GSRCC using a reliable and reproducible DIA-PCT method. This study objectives include characterizing the heterogeneity of GSRCC, performing molecular typing, identifying potential biomarkers and therapeutic targets, and providing a resource for stratified analysis of GSRCC. To achieve these goals, the investigators selected a cohort of 112 GSRCC patients from a pool of over 10,000 gastric cancer patients and conducted a proteomic analysis using the DIA-PCT method. This meticulous approach revealed four novel proteomic subtypes of GSRCC, each exhibiting unique molecular characteristics. Additionally, the investigators discovered that PRDX2 and DDX27 can serve as predictive biomarkers for GSRCC, which were further validated in an independent cohort of 75 GSRCC patients. Furthermore, the investigators paid particular attention to the MLT-GSRCC subgroup and identified three distinct proteomic clusters among MLT-GSRCC patients. Subtype 2 within this subgroup demonstrated the poorest prognosis. Through a rigorous screening process, the investigators determined potential targets for the treatment of GSRCC. In conclusion, these findings contribute to the investigators understanding of the heterogeneity of GSRCC and provide valuable resources for future clinical stratification and targeted treatment strategies.

Biological samples are used for proteomic analysis.

Mechanism of Gastric Signet Ring Cell Carcinoma Based on Microproteomics

This study does not involve drug clinical trials but focuses on ensuring the confidentiality of patient information. To protect patient privacy, a coding system was used instead of real names when entering patient information such as names and ages. Each patient was assigned a study identification number upon enrollment. Throughout the entire study, only the main researchers in the research team have the authority to access the true personal data of patients obtained from the electronic database (such as names and ages), and it is strictly prohibited to circulate or share this information. During the publication of the research article, the main researchers in the research team will use sample coding to replace patient privacy information (such as names) to achieve de-identification. Additionally, the protection of personal information for study participants must be maintained throughout the entire research process, and it is strictly forbidden to circulate or leak such information.

The samples diagnosed as GSRCC by pathology were selected as the samples with signet ring cell content \> 70% as judged by 2 pathologists of associate chief physician or above and without previous radiotherapy and chemotherapy. Tumor tissues and paired nat were collected from the same patient at the time of tumor resection and stored in formalin-fixed paraffin embedding (FFPE). Liquid chromatography-mass spectrometry (LC-MS) was used to detect the proteomics in the samples. The proteins in the samples were extracted, and the proteomics in the samples was detected by LC-MS. Qualitative and quantitative analysis was performed to detect the types and content of proteins in the samples.

Zhejiang Cancer Hospital

Secretary of the party committee

Symptoms and General Pathology

Blood and Lymph Conditions

Immune System Diseases

Infections

Skin and Connective Tissue Diseases

Diseases and Abnormalities at or Before Birth

Carcinoma, Squamous Cell

Syndrome

Recurrence

Lymphoma

Lymphoma, T-Cell

Mycoses

Carcinoma, Ductal

Carcinoma, Basal Cell

Mycosis Fungoides

Skin Neoplasms

Lymphoma, T-Cell, Cutaneous

Sezary Syndrome

Lymphoma, Large-Cell, Anaplastic

Carcinoma, Merkel Cell

Adenocarcinoma, Mucinous

Paget Disease, Extramammary

Carcinoma, Skin Appendage

Adenocarcinoma, Sebaceous

Keratoacanthoma

Muir-Torre Syndrome

Eccrine Porocarcinoma

Adenocarcinoma, Papillary

Carcinoma, Basosquamous

Sweat Gland Neoplasms

Lymphoma, Non-Hodgkin

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Disease Attributes

Neoplasms, Squamous Cell

Communicable Diseases

Bacterial Infections

Bacterial Infections and Mycoses

Neoplasms, Basal Cell

Polyomavirus Infections

Virus Diseases

DNA Virus Infections

Tumor Virus Infections

Carcinoma, Neuroendocrine

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms, Nerve Tissue

Skin Diseases

Neoplasms, Adnexal and Skin Appendage

Sweat Gland Diseases

Lymphosarcoma

Cutaneous T-cell Lymphoma

Anaplastic Large Cell Lymphoma

Merkel Cell Carcinoma

Extramammary Paget Disease

Hidradenocarcinoma

Microcystic Adnexal Carcinoma

Apocrine Carcinoma

Neuroendocrine Tumor

Neuroepithelioma

Antineoplastic Agents

All Drugs and Chemicals

Nivolumab

Talimogene laherparepvec

Antineoplastic Agents, Immunological

Immune Checkpoint Inhibitors

Patients receive talimogene laherparepvec IT and nivolumab IV over 30 minutes on day 1. Cycles repeat every 21 days for cycle 1 then every 14 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients undergo, CT scan or PET/CT on study. Patients also undergo blood sample collection and biopsies on study.

Biopsy

Biospecimen Collection

Computed Tomography

Laboratory Biomarker Analysis

Positron Emission Mammography

Talimogene Laherparepvec

Ann (Annie) W Silk

This phase II trial studies how well talimogene laherparepvec and nivolumab work in treating patients with lymphomas that do not responded to treatment (refractory) or non-melanoma skin cancers that have spread to other places in the body (advanced) or do not responded to treatment. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving talimogene laherparepvec and nivolumab may work better compared to usual treatments in treating patients with lymphomas or non-melanoma skin cancers.

PRIMARY OBJECTIVE:

I. To determine the frequency of patients responding (response rate) to talimogene laherparepvec monotherapy.

SECONDARY OBJECTIVES:

I. To determine the local response rate to talimogene laherparepvec in injected tumors.

II. To determine the response rate to talimogene laherparepvec + nivolumab (NIVO).

III. To identify potential pre-treatment and on-treatment correlative biomarkers of local and systemic immune response.

OUTLINE:

Patients receive talimogene laherparepvec intratumorally (IT) and nivolumab intravenously (IV) over 30 minutes on day 1. Cycles repeat every 21 days for cycle 1 then every 14 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) scan or positron emission tomography (PET)/CT scan on study. Patients also undergo blood sample collection and biopsies on study.

After completion of study treatment, patients are followed up every 12 weeks for 3 years.

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors

Will be analyzed using descriptive statistics. A test of proportions will be performed.

Will be analyzed using descriptive statistics. Logistic regression of response rate on the variable will be performed.

Will be analyzed using descriptive statistics. Test of proportions and logistic regression will be performed.

Will be assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

Will be defined as complete response or partial response lasting \>= 6 months.

Will be assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.

National Cancer Institute (NCI)

Gastrointestinal Neoplasms

Digestive System Neoplasms

Stomach Diseases

Gastrointestinal Diseases

christophe mariette, MD, PhD

Background • A major increase in incidence of signet ring cell adenocarcinomas (ADCI) of the upper digestive tract in western countries

* Discordant results in the literature concerning the prognosis value of the presence of signet ring cells.
* Preliminary data suggesting (i) an advanced stage at time of diagnosis, (ii) more often in the form of carcinose, (iii) a more pejorative prognosis, (iv) a recurrence more frequent, more quickly, and more often in the form of peritoneal carcinose, (v) a chemo resistance (vi) the need for a specific therapeutic strategy compared to non-signet ring cell adenocarcinomas.

Primary objective To test the hypothesis that 5-year survival rate is significantly lower in the signet ring cells (SRC) adenocarcinoma when compared to non-SRC adenocarcinoma in the upper digestive tract

Secondary objectives

* Impact of neoadjuvant CT on overall survival
* Impact and differential diagnostic value of linitis
* R0 resection rates
* 3 years recurrence free survival
* Overall 3 years survival
* Prognostic factors
* Prognostic value of the presence of a minority quota of signet ring cell
* Objective response rate after medical treatment (chemotherapy, radiochemotherapy) in non-resected patients
* Tolerance of (radio) chemotherapy for ADCI

Methodology Intention to treat retrospective case-control multicentric study A pairing on demographic criteria (age, sex, ASA score, center) and tumor criteria (TNM stage) will be done to ensure comparability in case control study groups.

Inclusion criteria All consecutive patients taken care of, for a proven histologically adenocarcinoma (ADCI and ADNCI) of the esophagus, the esogastric junction, or the stomach, in surgical or medical oncology investigator centers, will be saved in a given database.

For whom the first consultation took place between January 1997 and January 2010

Exclusion criteria Histological type other than adenocarcinoma Other localization than esogastric junction, esophagus or stomach

Planned study period The data will be collected over a period from January 1997 to January 2010.

The objective is to complete the data collection for summer 2010.

stomach cancer signet ring cell carcinoma prognosis chemotherapy

Prognosis of Signet Ring Cells in Upper Digestive Neoplasms

Has the Quota of Signet Ring Cells an Influence on Prognosis and Treatment Strategy in the Upper GI Tract Adenocarcinomas?

University Hospital, Lille

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Mechanism of Gastric Signet Ring Cell Carcinoma Based on Microproteomics	NCT05985577	Gastric Cancer Signet Ring Cel...	Without any int...	-	Zhejiang Cancer Hospital
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers	NCT02978625	Adenoid Cystic ... Adnexal Carcino... Anaplastic Larg... Anaplastic Larg... Apocrine Carcin... Cylindrocarcino... Digital Papilla... Endocrine Mucin... Extramammary Pa... Extraocular Cut... Hidradenocarcin... Keratoacanthoma Malignant Sweat... Merkel Cell Car... Microcystic Adn... NK-Cell Lymphom... Papillary Adeno... Porocarcinoma Primary Cutaneo... Recurrent Matur... Recurrent T-Cel... Refractory Anap... Refractory Matu... Refractory Merk... Refractory Myco... Refractory Prim... Refractory Skin... Refractory T-Ce... Sezary Syndrome Signet Ring Cel... Skin Basal Cell... Skin Basosquamo... Skin Squamous C... Spiradenocarcin... Squamoid Eccrin... Squamous Cell C... Sweat Gland Car... Trichilemmal Ca... Vulvar Squamous...	Biopsy Biospecimen Col... Computed Tomogr... Laboratory Biom... Nivolumab Positron Emissi... Talimogene Lahe...	18 Years -	National Cancer Institute (NCI)
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers	NCT02978625	Adenoid Cystic ... Adnexal Carcino... Anaplastic Larg... Anaplastic Larg... Apocrine Carcin... Cylindrocarcino... Digital Papilla... Endocrine Mucin... Extramammary Pa... Extraocular Cut... Hidradenocarcin... Keratoacanthoma Malignant Sweat... Merkel Cell Car... Microcystic Adn... NK-Cell Lymphom... Papillary Adeno... Porocarcinoma Primary Cutaneo... Recurrent Matur... Recurrent T-Cel... Refractory Anap... Refractory Matu... Refractory Merk... Refractory Myco... Refractory Prim... Refractory Skin... Refractory T-Ce... Sezary Syndrome Signet Ring Cel... Skin Basal Cell... Skin Basosquamo... Skin Squamous C... Spiradenocarcin... Squamoid Eccrin... Squamous Cell C... Sweat Gland Car... Trichilemmal Ca... Vulvar Squamous...	Biopsy Biospecimen Col... Computed Tomogr... Laboratory Biom... Nivolumab Positron Emissi... Talimogene Lahe...	18 Years -	National Cancer Institute (NCI)
Prognosis of Signet Ring Cells in Upper Digestive Neoplasms	NCT01249859	Signet Ring Cel... Stomach Disease Oesophagus Prognostic Case-control St...		18 Years - 95 Years	University Hospital, Lille

Spots Global Cancer Trial Database for signet ring cell carcinoma